[Low-dose lung cancer screening programs - European outlook]

Lung cancer has a high incidence and mortality throughout the world. For a long time no screening methods were available that could detect early, operable lung cancers, and could significantly lower mortality. The NLST trial, published in 2013, and the NELSON trial in 2019 both proved that low-dose CT lung cancer screening in a targeted group of at-risk people lowers long-term mortality significantly. In parallel to, or following these studies pilot programs were started in several European countries, including Hungary. In this article different European approaches are presented, when available including the results thereof.